Welcome to our dedicated page for OPTIMI HEALTH news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on OPTIMI HEALTH stock.
Optimi Health Corp. (OPTHF) is a leading Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA. The company recently obtained a Drug Establishment Licence (DEL) from Health Canada, confirming compliance with Good Manufacturing Practices (GMP). This allows Optimi to supply MDMA and psilocybin capsules to patients with PTSD and Treatment-Resistant Depression under Australia's Authorized Prescriber Scheme and export to regulated jurisdictions globally. Optimi aims to be the trusted global supplier of safe drug candidates by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.
Rhea-AI Summary
Optimi Health Corp. announces its role as a Presenting Sponsor at the 4th Annual Psychedelic Therapeutics and Drug Development Conference. CEO Bill Ciprick will speak on the future of GMP psychedelic manufacturing. The event aims to explore the challenges and opportunities in developing psychedelic therapies. Optimi aims to showcase its strength as a top GMP psychedelics manufacturer committed to quality and safety standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.62%
Tags
-
Rhea-AI Summary
Optimi Health Corp. signs its first international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv University, marking its entry into the Israeli market. The collaboration aims to support research on the effects of MDMA on alcohol addiction in animal models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
-
Rhea-AI Summary
Optimi Health Corp. closed the first tranche of a private placement, led by co-founders JJ Wilson and Dane Stevens, raising CAD$555,010. The company issued 1,850,033 units at CAD$0.30 per unit. Each unit consists of a common share and a warrant. The proceeds will be used to obtain a Drug Establishment License, facilitate commercialization, and for general working capital. Founders committed to a one-year lock-up period for their shares, showing dedication to commercializing the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.55%
Tags
Rhea-AI Summary
Optimi Health Corp. congratulates Lykos Therapeutics on FDA's acceptance of NDA for PTSD therapy. Optimi showcases GMP MDMA production process. FDA's priority review highlights the potential breakthrough in mental healthcare. Optimi aligns with Lykos protocol for MDMA encapsulation. Optimi emphasizes commitment to quality assurance and transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
-
Rhea-AI Summary
Optimi Health Corp. announces a non-brokered private placement of up to 5,000,000 units at CAD$0.30 per unit, with gross proceeds of up to CAD$1,500,000. The company intends to use the net proceeds to obtain its Drug Establishment License, commercialization, and for general working capital. Insiders of the company may participate in the offering for up to $605,000. The issuance of units to insiders will be considered a 'related party transaction'. All securities issued under the offering will be subject to a hold period expiring 4 months and 1 day after issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
-
News
Rhea-AI Summary
Optimi Health Corp. is hosting a webinar titled 'Know Your Drug Candidate: Safeguarding Quality in Psychedelic Therapy' to provide insights into the safety and quality standards of their psychedelic drug candidates. The company is the only end-to-end, publicly listed psychedelics company currently offering its drug candidates at scale to address accessibility through lower costs. The FDA is expected to decide on the acceptance of the New Drug Application for MDMA-Assisted Therapy for PTSD by February 12, 2024, which has the potential to reshape the industry landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
Rhea-AI Summary
Optimi Health Corp. has been granted an amendment to its Health Canada Controlled Drugs and Substances Licence, allowing substantial increases in the quantities of MDMA, MDA, and 2CB. This strategic licensing plan positions the company as an industry-leading psychedelics drug manufacturer, preparing for potential approval of MDMA by the U.S. Food and Drug Administration in 2024. The company's 2024 strategic licensing plan includes approvals for a Drug Master File (DMF) and Drug Establishment Licence (DEL) to ensure regulatory compliance and transparency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.62%
Tags
-
Rhea-AI Summary
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) proudly announces the granting of its Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone ('MDP2P') by Health Canada, allowing the company to import MDP2P for formulating and verifying MDMA drug candidates. This achievement positions Optimi to produce MDMA at reduced costs, aligning with market demand and the recent NDA submission by MAPS PBC to the FDA. The successful encapsulation of MDMA into 40mg and 60mg dosage formats further solidifies Optimi's strategic position as a premier provider of encapsulated MDMA in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.08%
Tags
-
Rhea-AI Summary
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) announced a supply agreement with Sunshine Earth Labs Ltd., a fellow biosciences company, to provide GMP quality-controlled substances for medicinal and research purposes. The partnership leverages the strengths of two reputable companies in the psychedelics industry, reinforcing British Columbia's standing as a hub for innovative advancements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
Rhea-AI Summary
Optimi Health Corp. (OPTI) has successfully harvested eight new natural Psilocybin genetics, solidifying its position as a leading psychedelic research and formulation company. The company is advancing its full spectrum, GMP extract quality program and has confirmed the product's potency and quality attributes for the duration of clinical trials. Optimi is also making GMP Psilocybin API available for encapsulation into standardized dosages or sale to other groups, expanding its reach and impact within the psychedelic research community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.74%
Tags
FAQ
What is the current stock price of OPTIMI HEALTH (OPTHF)?
The current stock price of OPTIMI HEALTH (OPTHF) is $0.1702 as of October 15, 2024.
What is the market cap of OPTIMI HEALTH (OPTHF)?
The market cap of OPTIMI HEALTH (OPTHF) is approximately 15.3M.
What is Optimi Health Corp. specialized in?
Optimi is a Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances like botanical psilocybin and MDMA.
What recent milestone did Optimi achieve?
Optimi obtained a Drug Establishment Licence (DEL) from Health Canada, affirming its compliance with Good Manufacturing Practices (GMP) to supply MDMA and psilocybin capsules for patients.
What is Optimi's goal in the pharmaceutical industry?
Optimi aims to be the top trusted supplier of safe drug candidates globally by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.
Where is Optimi's manufacturing facility located?
Optimi's manufacturing facilities totaling 20,000 square feet are located in Princeton, British Columbia.
What licenses does Optimi hold?
Optimi holds a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL), enabling the production of GMP-grade products and APIs.
How does Optimi plan to support global psychedelic research?
Optimi has completed its first international shipment of MDMA to Israel, supporting global research and innovation in the psychedelic field.
What is Optimi's key achievement in terms of export?
Optimi received the necessary Export Permit from Health Canada, confirming its ability to export controlled substances internationally.
What services does Oak Hill Financial Inc. provide to Optimi?
Oak Hill Financial Inc. provides comprehensive investor relations, business, and capital markets advisory services to Optimi at a rate of CDN$12,000 per month.
How does Optimi plan to expand its shareholder base?
Optimi aims to engage new investors and communicate its corporate milestones effectively through partnerships like Oak Hill Financial Inc.
What makes Optimi unique in the pharmaceutical industry?
Optimi's unique capabilities lie in producing scalable psychedelic formulations for transformational human experiences while meeting the highest quality and safety standards.
OPTIMI HEALTH CORP
OTC:OPTHF
OPTHF Rankings
OPTHF Stock Data
15.34M
75.57M
16.52%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
United States of America
Garibaldi Highlands